Takeshi Tada

Takeshi Tada

Auto-generated profile, based on publicly available information

Takeshi Tada

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Amelia ParkerAmelia Parker
Amelia Parker
LTLeila Toulabi
Leila Toulabi
TOTakahiro Oike
Takahiro Oike
YKYasuyuki Kanke
Yasuyuki Kanke
DPDaxeshkumar Patel
Daxeshkumar Patel
CHCurtis C. Harris
Curtis C. Harris
The metabolic dependencies of cancer cells have substantial potential to be exploited to improve the diagnosis and treatment of cancer. Creatine riboside (CR) is identified as a urinary metabolite associated with risk and prognosis in lung and liver cancer. However, the source of high CR levels in patients with cancer as well as their implications for the treatment of these aggressive cancers remain unclear. By integrating multiomics data on lung and liver cancer, we have shown that CR is a cancer cell–derived metabolite. Global metabolomics and gene expression analysis of human tumors and matched liquid biopsies, together with functional studies, revealed that dysregulation of the mitochondrial urea cycle and a nucleotide imbalance were associated with high CR levels and indicators of a poor prognosis. This metabolic phenotype was associated with reduced immune infiltration and supported rapid cancer cell proliferation that drove aggressive tumor growth. CRhi cancer cells were auxotrophic for arginine, revealing a metabolic vulnerability that may be exploited therapeutically. This highlights the potential of CR not only as a poor-prognosis biomarker but also as a companion biomarker to inform the administration of arginine-targeted therapies in precision medicine strategies to improve survival for patients with cancer.

5 June 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Purpose: Nonsmokers account for 10% to 13% of all lung cancer cases in the United States. Etiology is attributed to multiple risk factors including exposure to secondhand smoking, asbestos, environmental pollution, and radon, but these exposures are not within the current eligibility criteria for early lung cancer screening by low-dose CT (LDCT). Experimental Design: Urine samples were collected from two independent cohorts comprising 846 participants (exploratory cohort) and 505 participants (validation cohort). The cancer urinary biomarkers, creatine riboside (CR) and N-acetylneuraminic acid (NANA), were analyzed and quantified using liquid chromatography–mass spectrometry to determine if nonsmoker cases can be distinguished from sex and age-matched controls in comparison with tobacco smoker cases and controls, potentially leading to more precise eligibility criteria for LDCT screening. Results: Urinary levels of CR and NANA were significantly higher and comparable in nonsmokers and tobacco smoker cases than population controls in both cohorts. Receiver operating characteristic analysis for combined CR and NANA levels in nonsmokers of the exploratory cohort resulted in better predictive performance with the AUC of 0.94, whereas the validation cohort nonsmokers had an AUC of 0.80. Kaplan–Meier survival curves showed that high levels of CR and NANA were associated with increased cancer-specific death in nonsmokers as well as tobacco smoker cases in both cohorts. Conclusions: Measuring CR and NANA in urine liquid biopsies could identify nonsmokers at high risk for lung cancer as candidates for LDCT screening and warrant prospective studies of these biomarkers.

15 August 2024
Verified
Other
Open access
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Distribution of CR and NANA metabolite levels in (A) Exploratory cohort and (B) Validation cohort in male and female participants. **** p<0.0001; * p<0.05; LCC, lung cancer cases; NS, Non-smokers; x͂ = median

15 August 2024
Verified
Other
Open access
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Distribution of CR and NANA metabolite levels in late-stage (III & IV) cases. **** p<0.0001, *** p<0.001; LS, late-stage (III & IV); x͂ = median

15 August 2024
Verified
Other
Open access
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Distribution of CR and NANA metabolite levels in AA and EA participants. **** p<0.0001* p<0.05; AA, African American; EA, European American; LCC, lung cancer cases; x͂ = median

15 August 2024
Verified
Other
Open access
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Distribution of CR and NANA metabolite levels in early-stage (I & II) cases. ****, p < 0.0001, ***, p < 0.001; ES, early-stage (I & II); x͂ = median